The estimated Net Worth of Cynthia Smith is at least 662 千$ dollars as of 11 August 2024. Ms. Smith owns over 2,302 units of Dicerna Pharmaceuticals Inc stock worth over 305,454$ and over the last 6 years she sold DRNA stock worth over 55,261$. In addition, she makes 300,950$ as Independent Director at Dicerna Pharmaceuticals Inc.
Cynthia has made over 6 trades of the Dicerna Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 2,302 units of DRNA stock worth 87,982$ on 11 August 2024.
The largest trade she's ever made was buying 15,000 units of Dicerna Pharmaceuticals Inc stock on 20 November 2019 worth over 52,800$. On average, Cynthia trades about 965 units every 54 days since 2018. As of 11 August 2024 she still owns at least 7,992 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Ms. Smith stock trades at the bottom of the page.
Cynthia Smith serves as Independent Director of the Company. Ms. Smith most recently served as Chief Commercial Officer and a member of the executive team of ZNS Pharma (NASDAQ: ZSPH), acquired by AstraZeneca (NYSE: AZN) in 2015 for approximately $2.7 billion, a position she held from June 2013 to December 2016. Prior to joining ZS Pharma, Ms. Smith served as Vice President, Market Access and Commercial Development at Affymax, Inc. Ms. Smith was employed at Affymax from October 2008 to March 2013. She held various leadership positions at Merck (NYSE: MRK) from June 2000 to October 2008. She previously served on the Board of Directors of Nivalis Therapeutics (NASDAQ: NVLS) from October 2016 to July 2017.Ms. Smith earned her Bachelor’s degree in communications from the University of North Carolina, a Master’s degree in public policy from Rutgers University, and an M.B.A. from The Wharton School, University of Pennsylvania. The Nominating and Corporate Governance Committee believes that Ms. Smith’s scientific and business experience, including her position as an executive officer of a biopharmaceutical company and key positions at a large global pharmaceutical company, provide her with the qualifications and skills to serve as a member of our Board of Directors.
As the Independent Director of Dicerna Pharmaceuticals Inc, the total compensation of Cynthia Smith at Dicerna Pharmaceuticals Inc is 300,950$. There are 10 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of 5,048,130$.
Cynthia Smith is 51, she's been the Independent Director of Dicerna Pharmaceuticals Inc since 2018. There are 10 older and 2 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
Cynthia's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over 233,644,011$ worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth 36,501,331$ . The most active insiders traders include Capital Management, Llc Kol...、Nicole Vitullo、Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,025,674$. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth 78,351$.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: